KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Research & Development (2016 - 2025)

Historic Research & Development for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $217.8 million.

  • Ionis Pharmaceuticals' Research & Development fell 91.33% to $217.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $881.5 million, marking a year-over-year decrease of 341.14%. This contributed to the annual value of $901.5 million for FY2024, which is 21.18% up from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' Research & Development stood at $217.8 million, which was down 91.33% from $217.5 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' Research & Development's 5-year high stood at $308.3 million during Q4 2022, with a 5-year trough of $139.3 million in Q2 2021.
  • For the 5-year period, Ionis Pharmaceuticals' Research & Development averaged around $206.0 million, with its median value being $214.2 million (2024).
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Research & Development skyrocketed by 7166.75% in 2022, and later crashed by 1677.64% in 2023.
  • Ionis Pharmaceuticals' Research & Development (Quarter) stood at $179.6 million in 2021, then skyrocketed by 71.67% to $308.3 million in 2022, then fell by 16.78% to $256.6 million in 2023, then decreased by 4.31% to $245.5 million in 2024, then decreased by 11.3% to $217.8 million in 2025.
  • Its last three reported values are $217.8 million in Q3 2025, $217.5 million for Q2 2025, and $200.8 million during Q1 2025.